Treats generalized tonic-clonic status epilepticus, and prevention and treatment of…. ANDA 40573, held by Acella. Phenytoin Sodium.
As of Nov 16, 2026, ANDA 40573 (Phenytoin Sodium), held by Acella, was first approved by FDA on Sep 13, 2006, with 4 approved supplements and 0 published complete response letters.
Parenteral Phenytoin Sodium Injection is indicated for the treatment of generalized tonic-clonic status epilepticus, and prevention and treatment of seizures occurring during neurosurgery. Intravenous Phenytoin Sodium Injection can also be substituted, as short-term use, for oral phenytoin. Parenteral Phenytoin should be used only when oral phenytoin administration is not possible.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 13, 2006 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Phenytoin Sodium50MG/ML · injectable;injection | Phenytoin Sodium | Rx |
| Oct 2, 2024 | Supplement 15Labeling · Standard review | Approved | None posted |
| Feb 16, 2021 | Supplement 13Labeling · Standard review | Approved | None posted |
| Oct 6, 2020 | Supplement 12Labeling · Standard review | Approved | None posted |
| Jan 27, 2011 | Supplement 9Labeling | Approved | None posted |
| Sep 13, 2006 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters